Better Mitochondrial Replacement: But Why?
By Ricki Lewis,
PLOS
| 06. 09. 2016
The disconnect was striking between the headline of the news release a few days ago – “Improved method for mitochondrial replacement therapy” – and the title of the paper to which it refers – “Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease.”
The news release reported changes in the experimental protocol for pronuclear transfer (PNT) a proposed way to prevent mitochondrial disease. Pronuclei house the genomes in egg and sperm. PNT places them into human fertilized ova whose nuclei have been removed, but whose mitochondria remain in the cytoplasm. The intent is to fashion fertilized ova missing the mitochondria from a woman who has a mitochondrial mutation, which she’d know from having a child with one of the dozen or so diseases caused by mutations in mitochondrial genes. (Additional conditions that affect mitochondria result from mutations in genes in the nucleus).
The paper, published yesterday online in Nature, is from Mary Herbert and colleagues at the Wellcome Trust Centre for Mitochondrial Research, Newcastle upon Tyne, United Kingdom.
It’s a clear, concise report of technically elegant and...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
